🔎 Trials Near Me

Beranda › Kanker Paru Non-Sel Kecil › Arkansas › Springdale

Uji klinis Kanker Paru Non-Sel Kecil di Springdale, AR

15 studi untuk Kanker Paru Non-Sel Kecil mencari peserta di lokasi sekitar Springdale (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Menerima pesertaFase 3
  • Highlands Oncology Group, PA, Springdale
  • Highlands Oncology Group, Springdale
  • Highlands Oncology Group, PA, Rogers · 10 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07144280

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Menerima pesertaFase 3
  • Highlands Oncology Group-Research Department ( Site 0062), Springdale
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06312137

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Menerima pesertaFase 3
  • Highlands Oncology Group, Springdale
  • Highlands Oncology Group, Rogers · 10 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07222566

Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

Menerima pesertaFase 1/2
  • Highlands Oncology Group, PA, Springdale
  • Highlands Oncology Group, PA, Rogers · 10 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07227298

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Menerima pesertaFase 3
  • Highlands Oncology Group, Springdale
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06890598

Pan-tumor MRD Study

Menerima pesertaStudi observasional
  • Highlands Oncology Group (HOG), Springdale
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06605404

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Menerima pesertaFase 3
  • Research Site, Springdale
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT06692738

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Menerima pesertaFase 2/3
  • Highlands Oncology Group - Springdale, Springdale
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT04613596

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Menerima pesertaFase 3
  • Highlands Oncology Group, Springdale
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT06119581

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Menerima pesertaFase 1
  • Highlands Oncology Group, Springdale
  • Highlands Oncology Group, Rogers · 10 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT04389632

BostonGene and Exigent Genomic INsight Study

Menerima pesertaStudi observasional
  • Highlands Oncology Group, Rogers · 10 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Feb 2025 · NCT06272864

Uji klinis Kanker Paru Non-Sel Kecil di kota lain

Studi lain di Springdale

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.